nach oben

International Ophthalmology

Erschienen in:

09.01.2020 | Review

Thyroid eye disease: current and potential medical management

verfasst von: Jessica M. Pouso-Diz, Jose M. Abalo-Lojo, Francisco Gonzalez

Erschienen in: International Ophthalmology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Thyroid eye disease (TED) is the most frequent extra-thyroid manifestation of Graves’ disease and it is more frequent in middle age and in female gender. Nowadays, the causal mechanisms of this disease are not completely understood, but the current available studies suggest that the main causative factor is the thyroid stimulating hormone receptor.

Materials and methods

To collect reports on TED medical management, a thorough literature search was performed in PubMed database. An additional search was made in Google Scholar to complete the collected items.

Results

Among the indentified risk factors, tobacco habit is the most relevant. The main criteria to choose a suitable treatment are the activity and severity of the disease. Support measures can be used to improve the patient’s symptoms in any phase of the disease. There is a large number of drugs proposed to manage TED, although with different reported rates of success.

Conclusions

Currently, the drugs of choice are corticosteroids in moderate-to-severe and in sight-threatening forms. The main problem of corticosteroids is their spectrum of side effects. Therefore, other alternatives are being suggested for medical management of this disease. The efficacy of these alternatives remains unclear.

De Groot L, Chrousos G, Dungan K et al (2000) Graves’ disease and the manifestations of thyrotoxicosis. Endotext, South Dartmouth

Abraham-Nordling M, Byström K, Törring O, Lantz M, Berg G, Calissendorf J et al (2011) Incidence of hyperthyroidism in Sweden. Eur J Endocrinol 165:899–905PubMed

Barrio-Barrio J, Sabater A, Bonet-Farriol E, Velázquez-Villoria Á, Galofré J (2015) Graves’ ophthalmopathy: VISA vs EUGOGO classification, assessment, and management. J Ophthalmol 2015:249125PubMedPubMedCentral

Bartalena L, Baldeschi L, Bobodoris K, Eckstein A, Kahaly G, Marcocci C et al (2016) The 2016 European thyroid association/European Group on Graves’ Orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid 5:9–26

Briceño C, Gupta S, Douglas R (2013) Advances in the management of thyroid eye disease. Int Ophthalmol 53:93–101

Rivera-Grana E, Lin P, Suhler E, Rosenbaum J (2015) Methotrexate as a corticosteroid-sparing agent for thyroid eye disease. J Clin Exp Ophthalmol 6:422PubMedPubMedCentral

Bartalena L (2013) Graves’ orbitopathy: imperfect treatments for a rare disease. Eur Thyroid J. 2:259–269PubMedPubMedCentral

Laurberg P, Berman D, Bülow Pedersen I, Andersen S, Carlé A (2012) Incidence and clinical presentation of moderate to severe graves’ orbitopathy in a Danish population before and after iodine fortification of salt. J Clin Endocrinol Metab 97:2325–2332PubMedPubMedCentral

McKeag D, Lane C, Lazarus J, Baldeschi L, Boboridis K, Dickinson A et al (2007) Clinical features of dysthyroid optic neuropathy: a European Group on Graves’ Orbitopathy (EUGOGO) survey. Br J Ophthalmol 91:455–458PubMed

10.

Wiersinga W (2007) Advances in treatment of active, moderate-to-severe Graves’ ophthalmopathy. Diabetes Endocrinol 5:134–142

11.

Inaba H, Martin W, De Groot A, Qin S, De Groot L (2006) Thyrotropin receptor epitopes and their relation to histocompatibility leukocyte antigen-DR molecules in Graves’ disease. J Clin Endocrinol Metab 91:2286–2294PubMed

12.

Akamizu T, Mori T, Nakao K (1997) Pathogenesis of Graves’ disease: molecular analysis of anti-thyrotropin receptor antibodies. Endocr J 44:633–646PubMed

13.

Inaba H, De Groot L, Akamizu T (2016) Thyrotropin receptor epitope and human leukocyte antigen in Graves’ disease. Front Endocrinol (Lausanne) 7:120

14.

Iyer S, Bahn R (2012) Immunopathogenesis of Graves’ ophthalmopathy: the role of the TSH receptor. Pract Res Clin Endocrinol Metab 26:281–289

15.

Tsui S, Naik V, Hoa N, Hwang C, Afifiyan N, Sinha Hikim A et al (2008) Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease. J Immunol 181:4387–4405

16.

Douglas R, Gianoukakis A, Kamat S, Smith T (2007) Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves’ disease may carry functional consequences for disease pathogenesis. J Immunol 178:3281–3287PubMed

17.

Douglas R, Naik V, Hwang C, Afifiyan N, Gianoukakis A, Sand D et al (2008) B cells from patients with Graves’ disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol 181:5768–5774PubMed

18.

Smith T, Kahaly G, Ezra D, Fleming J, Dailey R, Tang R et al (2017) Teprotumumab for thyroid-associated ophthalmopy. N Engl J Med 376:1748–1761PubMedPubMedCentral

19.

Khong J, McNab A, Ebeling P, Craig J, Selva D (2016) Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. Br J Ophthalmol 100:142–150PubMed

20.

Mackay F, Browning J (2002) BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2:465–475PubMed

21.

Lied G, Berstad A (2011) Functional and clinical aspects of the B-cell-activating factor (BAFF): a narrative review. Scand J Immunol 73:1–7PubMed

22.

Leandro M, Cambridge G (2013) Expression of B cell activating factor (BAFF) and BAFF-biding receptors in rheumatoid arthritis. J Rheumathol 40:1247–1250

23.

Theodorou E, Nezos A, Antypa E, Ioakeimidis D, Koutsilieris M, Tektonidou M et al (2018) B-cell activating factor and related genetic variants in lupus related atherosclerosis. J Autoimmun 92:87–92PubMed

24.

Zhao Y, Li J, Wei B, Xu Z (2015) BAFF level increased in patients with autoimmune hemolytic anemia. Int J Clin Exp Med 8:2876–3882

25.

van Steensel L, Dik W (2010) The orbital fibroblast: a key player and target for therapy in Graves’ ophthalmopathy. Orbit 29:202–206PubMed

26.

van Steensel L, Hooijkaas H, Paridaens D, van de Bosch W, Kuijpers R, Drexhage H et al (2012) PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves’ ophthalmopathy patients. J Clin Endocrinol Metab 97:944–953

27.

Virakul S, van Steensel L, Dalm V, Paridaens D, van Hagen P, Dik W (2014) Platelet-derived growth factor: a key factor in the pathogenesis of Graves’ ophthalmopathy and potential target for treatment. Eur Thyroid 3:217–226

28.

Dik W, Virakul S, van Steensel L (2016) Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves’ ophthalmopathy. Exp Eye Res 142:83–91PubMed

29.

Bahn R (2010) Graves’ ophthalmopathy. N Engl J Med 362:726–738PubMedPubMedCentral

30.

Smith T (2010) Pathogenesis of Graves’ orbitopathy: a 2010 update. J Endocrinol 33:414–421

31.

Mourist M, Prummel M, Wiersinga W, Koornneef L (1997) Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 47:9–14

32.

Campi I, Vannucchi G, Salvi M (2016) Therapy of endocrine disease: endocrine dilemma: management of Graves’ orbitopathy. Eur J Endocrinol 175:117–133

33.

Salvi M (2012) EUGOGO Atlas: EUGOGO protocol for assessment of Graves’ orbitopathy and completion of case record form Milan: EUGOGO

34.

Werner S (1969) Classification of the eye changes of Graves’ disease. Am J Ophthalmol 68:646–648PubMed

35.

Werner S (1977) Modification of the classification of the eye changes of Graves’ disease. Am J Ophthalmol 83:725–727PubMed

36.

Prummel M, Wiersinga W (1993) Smoking and risk of Graves’ disease. JAMA 169:479–482

37.

Wiersinga W (2013) Smoking and thyroid. Clin Endocrinol (Oxf) 79:145–151

38.

Bartalena L, Marcocci C, Tanda M, Manetti L, Dell’Unto E, Bartolomei M et al (1998) Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med 129:632–635PubMed

39.

Pfeilschifter J, Ziegler R (1996) Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol (Oxf) 45:477–481

40.

Eckstein A, Quadbeck B, Mueller G, Rettenmeier A, Hoermann R, Mann K et al (2003) Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Br J Ophthalmol 87:773–776PubMedPubMedCentral

41.

Bartalena L (2012) Prevention of Graves’ ophthalmopathy. Best Pract Res Clin Endocrinol Metab 26:371–379PubMed

42.

Krassas G, Segni M, Wiersinga W (2005) Childhood Graves’ ophthalmopathy: results of a European questionnaire study. Eur J Endocrinol 153:515–521PubMed

43.

Eckstein A, Lösch C, Glowacka D, Schott M, Mann K, Esser J et al (2009) Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves’ ophthalmopathy. Br J Ophthalmol 93:1052–1056PubMed

44.

Termote K, Decallonne B, Mombaerts I (2014) The influence of prior hyperthyroidism on euthyroid Graves’ ophthalmopathy. J Ophthalmol 22:426898

45.

Perros P, Hegedüs L, Bartalena L, Marcocci C, Kahaly G, Baldeschi L et al (2017) Graves’ orbitopathy are a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis 12:72PubMedPubMedCentral

46.

Bartley G, Fatourechi V, Kadrmas E, Jacobsen S, Ilstrup D, Garrity J et al (1996) Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol 121:284–290PubMed

47.

Bartalena L, Marccocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A (1989) Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 321:1349–1352PubMed

48.

Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda M, Dell’Unto E et al (1998) Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med 338:73–78PubMed

49.

Lai A, Sassi L, Compri E, Marino F, Sivelli P, Piantanida E et al (2010) Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves’ orbitopathy: a retrospective cohort study. J Clin Endocrinol Med 95:1333–1337

50.

Negro R, Attanasio R, Grimaldi F, Guglielmi R, Papini E, AME (Associazione Medici Endocrinology) et al (2016) A 2015 Italian survey of clinical practice patterns in the management of Graves’ disease: comparison with European and North American surveys. Eur Thyroid J 5:112–119PubMedPubMedCentral

51.

Vannucchi G, Campi I, Covelli D, Dazzi D, Currò N, Simonetta S et al (2009) Graves’ orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis. J Clin Endocrinol Metab 94:3381–3386PubMed

52.

Träisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J et al (2009) Thyroid-associated ophthalmopathy after treatment for Graves’ hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 94:3700–3707PubMed

53.

Tallstedt L, Lundell G, Blomgren H, Bring J (1994) Does early administration of thyroxine reduce the development of Graves’ ophthalmopathy after radioiodine treatment? Eur J Endocrinol 130:494–497PubMed

54.

Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J (2005) A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active graves’ ophthalmopathy. J Clin Endocrinol Metab 90:5321–5323PubMed

55.

Watanabe N, Noh J, Kozaki A, Iwaku K, Sekiya K, Kosuga Y et al (2015) Radioiodine-associated exacerbation of Graves’ orbitopathy in the Japanese population: randomized prospective study. J Clin Endocrinol Metab 100:2700–2708PubMed

56.

Gerding M, van der Meer J, Broenink M, Bakker O, Wiersinga W, Prummel M (2000) Association of thyrotropin receptor antibodies with the clinical features of Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 52:267–271

57.

Eckstein A, Plicht M, Lax H, Neuhäuser M, Mann K, Lederbogen S et al (2006) Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of disease. J Clin Endocrinol Metab 91:3464–6470PubMed

58.

Marcocci C, Kahaly G, Krassas G, Bartalena L, Prummel M, Stahl M et al (2011) Selenium and the course of mild Graves’ orbitopathy. N Engl J Med 364:1920–1931PubMed

59.

Morgenstern K, Evanchan J, Foster J, Cahill K, Burns J, Holck D et al (2004) Botulinum toxin type a for dysthyroid upper eyelid retraction. Ophthalmic Plast Reconstr Surg 20:181–185PubMed

60.

Costa P, Saraiva F, Pereira I, Monteiro M, Matayoshi S (2009) Comparative study of Botox injection treatment for upper eyelid retraction with 6-month follow-up in patients with thyroid eye disease in the congestive or fibrotic stage. Eye (London) 23:767–773

61.

Nava Castañeda A, Tovilla Canales J, Garnica Hayashi L, Velasco Y Levy A (2017) Management of upper eyelid retraction associated with dysthyroid orbitopathy during the acute inflammatory phase with botulinum toxin type A. J Fr Ophtthalmol 40:279–284

62.

Marcocci C, Marinò M (2012) Treatment of mild, moderate-to-severe and very severe Graves’ orbitopathy. Best Pract Res Clin Endocrinol Metab 26:325–337PubMed

63.

Bhatti M, Dutton J (2014) Thyroid eye disease: therapy in the active phase. Best Pract Res Clin Endocrinol Metab 34:186–197

64.

Kumari R, Chandra Saha B (2018) Advances in the management of thyroid eye disease: an overview. Int Ophthalmol 38:2247–2255PubMed

65.

Duntas L, Benvenga S (2015) Selenium: an element for life. Endocrine 48:756–775PubMed

66.

Wu Q, Rayman M, Lv H, Schomburg L, Cui B, Gao C et al (2015) Low population selenium status is associated with increased prevalence of thyroid disease. J Clin Endocrinol Metab 100:4037–4047PubMed

67.

Vunta H, Davis F, Palempalli U, Bhat D, Arner R, Thompson J et al (2007) The anti-inflammatory effects of selenium are mediated through 15-deoxy-Delta 12,14-prostaglandin J2 in macrophages. J Biol Chem 282:17964–17973PubMed

68.

Saranac L, Zivanovic S, Bjelakovic B, Stamenkovic H, Novak M, Kamenov B (2011) Why is the thyroid so prone to autoimmune disease? Horm Res Paediatr 75:157–165PubMed

69.

Schomburg L (2011) Selenium, selenoproteins and the thyroid gland: interactions in health and disease. Nat Rev Endocrinol 8:160–171PubMed

70.

Ventura M, Melo M, Carrilho F (2017) Selenium and thyroid disease: from pathophysiology to treatment. Int J Endocrinol 2017:1297658PubMedPubMedCentral

71.

Carlson B, Yoo M, Shrimali R, Irons R, Gladyshev V, Hatfield D et al (2010) Role of selenium-containing proteins in T-cell and macrophage function. Proc Nutr Soc 69:300–310PubMedPubMedCentral

72.

Vrca V, Skerb F, Cepelak I, Romic Z, Mayer L (2004) Supplementation with antioxidants in the treatment of Graves’ disease; the effect on glutathione peroxidase activity and concentration of selenium. Clin Chim Acta 341:55–63PubMed

73.

Kahaly G, Riedl M, König J, Diana T, Schomburg L (2017) Double-blind, placebo-controlled, randomized trial of selenium in Graves’hiperthyroidism. J Clin Endocrinol Metab 102:4333–4341PubMed

74.

Strianese D (2017) Update of Graves’ disease: advances in treatment of mild, moderate and severe thyroid eye disease. Curr Opin Ophthalmol 28:505–513PubMed

75.

Stranges S, Navas-Acien A, Rayman M, Guallar E (2010) Selenium status and cardiometabolic health: state of evidence. Nutr Cardiovasc Dis 20:754–760

76.

Rayman M (2012) Selenium and human health. Lancet 379:12561268

77.

Rocourt C, Cheng W (2013) Selenium supranutrition: are the potential benefits of chemoprevention outweighed by the promotion of diabetes and insulin resistance? Nutrients 5:1349–1365PubMedPubMedCentral

78.

Heufelder A, Wenzel B, Bahn R (1993) Glucocorticoids modulate the synthesis and expression of a 72 kDa heat shock protein in cultured Graves’ retroocular fibroblast. Acta Endocrinol (Copenh) 128:41–50

79.

Krassas G, Heufelder A (2001) Immunosuppressive therapy in patients with thyroid eye disease: an overview of current concepts. Eur J Endocrinol 144:311–318PubMed

80.

Zang S, Ponto K, Kahaly G (2011) Clinical review: intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 96:320–332PubMed

81.

Ayabe R, Rootman D, Hwang C, Ben-Artzi A, Golberg R (2014) Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease. Ophthal Plast Reconstr Surg 30:415–419PubMed

82.

Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, Ezrachi D, Shimon I, Leibovici L (2009) Treatment modalities for Graves’ ophthalmopathy: systematic review and metaanalysis. J Clin Endocrinol Metab 94:2708–2716PubMed

83.

Mou P, Jiang L, Zhang Y, Li Y, Lou H, Zeng C et al (2015) Common immunosuppressive monotherapy for Graves’ ophthalmopathy: a meta-analysis. PLoS ONE 10:e0139544PubMedPubMedCentral

84.

Kahaly G, Pitz S, Hommel G, Dittmar M (2005) Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab 90:5234–5240PubMed

85.

Bartalena L, Pinchera A, Marcocci C (2000) Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev 21:168–199PubMed

86.

Sisti E, Coco B, Menconi F, Leo M, Rocchi R et al (2015) Intravenous glucocorticoid therapy for Graves’ ophthalmopathy and acute liver damage: an epidemiological study. Eur J Endocrinol 172:269–276PubMed

87.

Bartalena L, Krassas G, Wiersinga W, Marcocci C, Salvi M et al (2012) Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopahty. J Clin Endocrinol Metab 97:4454–4463PubMed

88.

Covelli D, Vannucchi G, Campi I, Currò N, D’Ambrosio R, Maggioni M et al (2015) Statins may increase the risk of liver dysfunction in patients treated with steroids for active Graves’ orbitopathy. J Clin Endocrinol Metab 100:1731–1737PubMed

89.

Sisti E, Menconi F, Leo M, Profilo M, Mautone T, Mazzi B et al (2015) Long-term outcome of Graves’ orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy. J Endocrinol Invest 38:661–668PubMed

90.

Macchia P, Bagattini M, Lupoli G, Vitale G, Fenzi G (2001) High-dose intravenous corticosteroid therapy for Graves’ ophthalmopathy. J Endocrinol Invest 24:152–158PubMed

91.

Smith J, Rosenbaum J (2001) A role methotrexate in the management of non-infectious orbital inflammatory disease. Br J Ophthalmol 85:1200–1224

92.

Emon M, Kodamullil A, Karki R, Younesi E, Hofmann-Apitius M (2017) Using drugs as molecular probes: a computational chemical biology approach in neurodegenerative disease. J Alzheimers Dis 56:677–686PubMedPubMedCentral

93.

Prummel M, Mourits M, Berghout A, Krenning E, van der Gaag R, Koornneef L et al (1989) Prednisone and cyclosporine in treatment of severe Graves’ ophthalmopathy. N Engl J Med 321:1353–1359PubMed

94.

Kahaly G, Schrezenmeir J, Krause U, Schweikert B, Meuer S, Muller W et al (1986) Ciclosporin and prednisone v. prednisone in treatment of Graves’ ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest 16:415–422PubMed

95.

Engel P, Gómez-Puerta J, Ramos-Casals M, Lozano F, Bosch X (2011) Therapeutic targeting of B cells for rheumatic autoimmune disease. Pharmacol Rev 63:127–156PubMed

96.

Salvi M, Vannucchi G, Currò N, Introna M, Rossi S, Bonara P et al (2012) Small dose of Rituximab for Graves’ orbitopathy: new insights into the mechanism of action. Arch Ophthalmol 130:122–124PubMed

97.

Salvi M, Vannucchi G, Beck-Peccoz P (2013) Potential utility of rituximab for Graves’ orbitopathy. J Clin Endocrinol Metab 98:4291–4299PubMed

98.

Salvi M, Vannucchi G, Currò N, Campi I, Covell D, Dazzi D et al (2015) Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 100:422–431PubMed

99.

Stan M, Garrity J, Carraza Leon B, Prabin T, Bradley E, Bahn R (2015) Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab 100:432–441PubMed

100.

Stan M, Salvi M (2017) Management of endocrine disease: rituximab therapy for Graves’ orbitopathy—lessons from randomized control trials. Eur J Endocrinol 176:101–109

101.

van Vollenhoven R, Emery P, Bingham CO, Keystone E, Fleischmann R, Furst D et al (2013) Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 72:1496–1502PubMed

102.

Descotes J (2009) Immunotoxicity of monoclonal antibodies. MAbs 1:104–111PubMedPubMedCentral

103.

Chen H, Shan S, Mester T, Wei Y, Douglas R (2015) TSH-Mediated TNFα production in human fibrocytes is inhibited by teprotumumab, an IGF-1R antagonist. PLoS ONE 10:e0130322PubMedPubMedCentral

104.

Donahue K, Gartlehner G, Jonas D, Lux L, Thieda P, Jonas B et al (2008) Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 148:124–134PubMed

105.

Komorowski J, Jankiewicz-Wika J, Siejka A, Lawnicka H, Kłysik A, Goś R et al (2007) Monoclonal anti-TNFalpha antibody (infliximab) in the treatment of patient with thyroid associated ophthalmopathy. Klin Oczna 109:457–460PubMed

106.

Paridaens D, van den Bosch W, van der Loos T, Krenning E, van Hagen P (2005) The effect of etanercept on Graves’ ophthalmopathy: a pilot study. Eye (Lond) 19:1286–1289

107.

de-Pablo-Gómez-de-Liaño L, Fernández-Vigo J, Troyano-Rivas J, Niño-Rueda C, Romo-López Á, Gómez de Liaño R (2018) Response to tocilizumab treatment in Graves’ ophthalmopathy by measuring rectus muscle thickness and chemosis using optical coherence tomography. Arch Soc Esp Oftalmol 93:386–391PubMed

108.

Pérez-Moreiras J, Alvarez-López A, Gómez E (2014) Treatment of active corticosteroid-resistant graves’ orbitopathy. Plast Reconstr Surg 30:162–167

109.

Pérez-Moreiras J, Gomez-Reino J, Maneiro J, Perez-Pampin E, Romo Lopez A, Rodríguez Alvarez F et al (2018) Efficacy of tocilizumab in patients with moderate to severe corticosteroid resistant graves orbitopathy: a randomized clinical trial. Am J Ophthalmol 195:181–190PubMed

110.

Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T et al (2014) Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol 41:15–23PubMed

111.

Chen H, Mester T, Raychaudhuri N, Kauh C, Gupta S, Smith T et al (2014) Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab 99:1635–1640

112.

Ye X, Bo X, Hu X, Cui H, Lu B, Shao J et al (2017) Efficacy and safety of mycophenolate mofetil in patients with active moderate-severe Graves’ orbitopathy. Clin Endocrinol (Oxf) 86:247–255

113.

Kahaly G, Riedl M, König J, Pitz S, Ponto K, Diana T et al (2018) Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol 6:287–298PubMed

114.

Seitz M (1999) Molecular and cellular effects of methotrexate. Curr Opin Rheumatol 11:226–232PubMed

115.

Bartalena L, Tanda M, Medea A, Marcocci C, Pinchera A (2002) Novel approaches to the management of graves’ ophthalmopathy. Hormones (Athens) 1:76–90

116.

Sipkova Z, Insull E, David J, Turner H, Keren S, Norris J (2018) Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a step-down approach. Clin Endocrinol (Oxf) 89:834–839

117.

Pasquali D, Vassallo P, Esposito D, Bonavolontà G, Bellastella A, Sinisi A (2000) Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves’ ophthalmopathy. J Mol Endocrinol 25:63–71PubMed

118.

Stan M, Garrity J, Bradley E, Woog J, Bahn M, Brennan M et al (2006) Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves’ ophthalmopathy. J Clin Endocrinol Metab 91:4817–4824PubMed

119.

Tanda L, Bartalena L (2006) Currently available somatostatin analogs are not good for Graves’ orbitopathy. J Endocrinol Invest 29:389–390PubMed

120.

Chang T, Liao S (2006) Slow-release lanreotide in Graves’ ophthalmopathy: a double-blind randomized, placebo-controlled clinical trial. J Endocrinol Invest 29:413–422PubMed

121.

Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002) SOM 230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and unique antisecretory profile. Eur J Endocrinol 146:707–716PubMed

122.

Tahara S, Murakami M, Kaneko T, Shimatsu A (2017) Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study. Endocrinol J 64:735–747

123.

Gerding M, van der Zant F, van Royen E, Koornneef L, Krenning E, Wiersinga W et al (1999) Octreotide-scintigraphy is a disease-activity parameter in Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 50:373–379

124.

Tang F, Chen X, Mao Y, Wan S, Ai S, Yang H et al (2017) Orbital fibroblast of Graves’ orbitopathy stimulated with proinflammatory cytokines promote B cell survival by secreting BAFF. Mol Cell Endocrinol 446:1–11PubMed

125.

Shen S, Chan A, Sfikakis P, Hsiu Ling A, Detorakis E, Boboridis K et al (2013) B-cell targeted therapy with rituximab for thyroid eye disease: closer to the clinic. Surv Ophthalmol 58:252–265PubMed

126.

McCoy A, Kim D, Gillespie E, Atkins S, Smith T, Douglas R (2014) Rituximab (Rituxan) therapy for severe thyroid-associated ophthalmopathy diminishes IGF-1R (+) T cells. Clin Endocrinol Metab 99:1294–1299

127.

van Vollenhoven R, Wax S, Li Y, Tak P (2015) Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial. Arthritis Reumatol 67:2828–2836

128.

Lenert A, Lenert P (2015) Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Drug Des Dev Ther 9:333–347

129.

Hewett K, Sanders D, Grove R, Broderick C, Rudo T, Bassiri A et al (2018) Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology 90:1425–1434

130.

van Steensel L, Paridaens D, van Meurs M, van Hagen P, van den Bosch W, Kuijpers R et al (2012) Orbit-infiltrating mast cells, monocytes and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in Graves’ ophthalmopathy. J Clin Endocrinol Metab 97:400–408

131.

van Steensel L, Paridaens D, Schrijver B, Dingjan G, van Daele P, van Hagen P et al (2009) Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves’ ophthalmopathy. Invest Ophthalmol Vis Sci 50:3091–3098PubMed

132.

Kim T, Rea D, Schwarz M, Grille P, Nicolini F, Rosti G et al (2013) Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 27:1316–1321PubMed

133.

Li H, Fitchett C, Kozdon K, Jayaram H, Rose G, Bailly M et al (2014) Independent adipogenic and contractile properties of fibroblasts in Graves’ orbitopathy: an in vitro model for the evaluation of treatments. PLoS ONE 9:e95586PubMedPubMedCentral

134.

Borriello A, Caldarelli I, Basile M, Bencivenga D, Tramontano A, Perrotta S et al (2011) The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells. PLoS ONE 6:e28555PubMedPubMedCentral

135.

Virakul S, Dalm V, Paridaens D, van den Bosch W, Hirankarn N, van Hagen P et al (2014) The tyrosine kinase inhibitor dasatinib effectively blocks PDGF-induced orbital fibroblast activation. Graefes Arch Clin Exp Ophthalmol 252:1101–1109PubMed

136.

Zhang L, Grennan-Jones F, Draman M, Lane C, Morris D, Dayan C et al (2014) Possible targets for nonimmunosuppressive therapy of Graves’ orbitopathy. J Clin Endocrinol Metab 99:1183–1190

137.

Kurtz J, Ray-Coquard I (2012) PI3 kinase inhibitors in the clinic: an update. Anticancer Res 32:2463–2470PubMed

138.

Gershengorn M, Neumann S (2012) Update in TSH receptor agonists and antagonists. J Clin Endocrinol Metab 97:4287–4292PubMedPubMedCentral

139.

Fleischmann R, Schechtman J, Bennett R, Handel M, Burmester G, Tesser J et al (2003) Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum 48:927–934PubMed

140.

Daifotis A, Koenig S, Chatenoud L, Herold K (2013) Anti-CD3 clinical trials in type 1 diabetes mellitus. Clin Immunol 149:268–278PubMed

141.

Rhiu S, Chae M, Lee E, Lee J, Yoon J (2014) Effect of tanshinone IIA in an in vitro model of Graves’ orbitopathy. Invest Ophthalmol Vis Sci 55:5900–5910PubMed

142.

Estcourt S, Hickey J, Perros P, Dayan C, Vaidya B (2009) The patient experience of services for thyroid eye disease in the United Kingdom: results of a nationwide survey. Eur J Endocrinol 16:483–487

Titel: Thyroid eye disease: current and potential medical management
verfasst von: Jessica M. Pouso-Diz
Jose M. Abalo-Lojo
Francisco Gonzalez
Publikationsdatum: 09.01.2020
Verlag: Springer Netherlands
Erschienen in: International Ophthalmology / Ausgabe 4/2020
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-019-01258-7

Neu im Fachgebiet Augenheilkunde

08.04.2024 | Therapieverfahren in der Augenheilkunde | CME

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Thyroid eye disease: current and potential medical management

Abstract

Introduction

Materials and methods

Results

Conclusions

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Springer Medizin

Abstract

Introduction

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients

Vitreous albumin redox state in open-angle glaucoma patients and controls: a pilot study

Potentially inappropriate prescriptions of anticholinergic medications in patients with closed-angle glaucoma

Intravitreal ranibizumab versus vitrectomy for recurrent vitreous haemorrhage after pars plana vitrectomy for proliferative diabetic retinopathy: a prospective study

Correction to: Ocular manifestations in celiac disease: an overview

Albrecht von Graefe (1828–1870) and his contributions to the development of ophthalmology

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde